Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company whose news flow centers on cancer drug development, capital markets activity and strategic transactions. The company publicly describes its focus as developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with its lead candidate plogosertib, a PLK1 inhibitor, being evaluated in patients with solid tumors and hematological malignancies.
News updates for CYCC often include clinical and preclinical developments related to plogosertib. Cyclacel has highlighted independent studies showing that biliary tract cancer and fibrolamellar hepatocellular carcinoma cells can be sensitive to PLK1 inhibition with plogosertib, as well as early Phase 1 data where oral plogosertib was reported to be well tolerated without dose-limiting toxicity in several dosing schedules. These items give investors and researchers insight into how external and internal data may shape the company’s oncology pipeline.
Cyclacel’s news also covers financial results and funding events, such as quarterly earnings updates, private placements of convertible preferred stock with accompanying warrants, and declarations of quarterly cash dividends on its 6% Convertible Exchangeable Preferred Stock. In addition, the company has issued releases on Nasdaq listing matters, including notices about minimum bid price compliance and announcements of reverse stock splits that affect the share structure while maintaining the CYCC ticker on The Nasdaq Capital Market.
Another recurring theme in Cyclacel news is strategic alternatives and corporate transactions. The company has discussed evaluating options to continue as a going concern and has announced an Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysia-based fire safety and protective equipment business, in a share and cash transaction subject to approvals. For investors tracking CYCC, following these news items helps monitor both the scientific progress of plogosertib and the company’s evolving capital structure and business direction.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) has successfully closed its underwritten public offering of 2,078,214 shares at $7.00 per share, raising approximately $14.5 million in gross proceeds. The offering included the full exercise of the underwriter's over-allotment option. Funds will be utilized for growth strategies, working capital, and R&D expenses. The offering was conducted under an effective shelf registration statement by the SEC. Oppenheimer & Co. Inc. served as the sole book-running manager for this public offering.
Cyclacel Pharmaceuticals will present at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 9:20 AM (EDT). CEO Spiro Rombotis will discuss the company's progress and key programs. Investors can attend one-on-one meetings during this virtual event.
A live webcast will be available on Cyclacel's website and archived for 90 days. The company specializes in developing innovative cancer treatments, focusing on a pipeline that includes fadraciclib and CYC140.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, CYCCP) announced a public offering of 1,807,143 shares of common stock at $7.00 per share, with gross proceeds anticipated to be approximately $12.65 million before expenses. The offering will close around March 16, 2021, pending customary conditions. Cyclacel plans to use the net proceeds for growth strategies, working capital, and R&D. Oppenheimer & Co. Inc. leads the offering, with additional co-managers involved. The offering is conducted under an effective shelf registration with the SEC.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced a proposed underwritten public offering of its common stock, which includes a 30-day option for underwriters to purchase an additional 15% of shares. The exact size and terms of the offering remain uncertain and depend on market conditions. Cyclacel plans to utilize net proceeds from this offering for general corporate purposes, including research and development expenses. Oppenheimer & Co. Inc. serves as the sole book-running manager for the offering, registered under Form S-3 with the SEC.
Cyclacel Pharmaceuticals reported financial results for Q4 and the full year 2020, with a net loss of $6.6 million for the quarter and $12.4 million for the year. Cash and cash equivalents stood at $33.4 million as of December 31, 2020, with additional proceeds of $4.3 million from warrant exercises post-year-end. The company announced plans to advance clinical studies of fadraciclib and CYC140 in various cancer types. Significant milestones for 2021 include the initiation of multiple Phase 1b/2 studies and the expected continuation of cash resources through early 2023.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will announce its fourth quarter and full year 2020 financial results on February 25, 2021. Following the announcement, a conference call will be held at 4:30 p.m. EST, which will be accessible through a live webcast. Cyclacel is engaged in developing innovative medications targeting cancer cell biology, including evaluating the CDK2/9 inhibitor fadraciclib and the PLK1 inhibitor CYC140 in clinical trials. For further details, the company encourages visiting their website.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will present at the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. A prerecorded presentation by CEO Spiro Rombotis will offer updates on the company's key programs, available for on-demand viewing starting February 15, 2021, at 9:00 AM ET. Registered attendees can also schedule one-on-one meetings with Cyclacel. The presentation will be live-streamed on the company's website and archived for 90 days.
Cyclacel Pharmaceuticals will present at the Lytham Partners Virtual Investor Growth Conference on October 8, 2020, at 8:00 AM ET. The event will feature a webcast available on Cyclacel's website. Cyclacel develops innovative cancer medicines focusing on cell cycle regulation and DNA damage response. The company is advancing programs like fadraciclib for solid tumors and sapacitabine for relapsed cancers. A replay of the presentation will be accessible after the event.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced an oral presentation for its CDK2/9 inhibitor, fadraciclib, at the 32nd EORTC-NCI-AACR Symposium 2020, taking place virtually on October 24-25, 2020. The presentation will highlight data from an ongoing Phase 1 study involving patients with advanced solid tumors. Notable findings include target engagement, biomarker suppression, and tumor shrinkage in affected patients. The study is evaluating fadraciclib both as a single agent and in combination with venetoclax for various cancers.
Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) reported a net loss of $2.2 million for Q2 2020, while cash and cash equivalents reached $25.3 million. The company anticipates sufficient resources to fund operations through 2022. Key highlights include promising results from its CDK2/9 inhibitor, fadraciclib, showing potential in treating advanced solid tumors and certain leukemias. A peer-reviewed study published in PLOS ONE emphasizes its therapeutic potential. No revenues were reported, and R&D expenses remained stable.
FAQ
What is the current stock price of Cyclacel Pharma (CYCC)?
What is the market cap of Cyclacel Pharma (CYCC)?
